Thirty-eight patients with advanced non-seminomatous germ cell tumours (NSGCTs) 
Cisplatin-based chemotherapy has dramatically improved the prognosis of patients with metastatic non-seminomatous germ cell tumours (NSGCTs). Patients with a low tumour burden are cured by chemotherapy in a high degree. However, patients with large-volume metastatic disease often achieve only a partial radiological remission. Residual masses consist of either necrosis/fibrosis, differentiated (mature) teratoma or viable undifferentiated tumour tissue. The nature of persisting radiological abnormalities can only be determined by surgical excision.
Several investigators recommend surgical resection of all post-chemotherapy residual masses if feasible (Donohue & Rowland, 1984; Tait et al., 1984; Tiffany et al., 1986; Harding et al., 1989; Toner et al., 1990; Qvist et al., 1991; Kulkarni et al., 1991) . However, as in some patients nothing but complete necrosis/fibrosis is found in all surgically removed specimens, the question arises of whether the number of surgical interventions could be reduced in selected patients. In this study, we analysed our experience with multiple surgical interventions following cisplatin-based chemotherapy of advanced NSGCTs. To determine the necessity of multiple surgical procedures, the histological findings at separate anatomical sites were compared. diagnosis was made according to the British Testicular Tumour Panel (Pugh, 1976) and World Health Organization (WHO) classification (Mostofi & Sobin, 1977 (Williams et al., 1987) . From 1984 to 1993 patients were mainly treated according to the ECBC protocol, including etoposide, cisplatin, bleomycin and cyclophosphamide (Gerl et al., 1993a,b) . Few patients received chemotherapy according to the PEB protocol (Williams et al., 1987) . A mean number of 5.6 cycles (range 4-14 cycles) of chemotherapy was administered prior to surgery. Patients with undifferentiated tumour resected at post-chemotherapy surgery routinely underwent two cycles of cisplatin-ifosfamide-based chemotherapy (Clemm et al., 1986 Table I. Follow-up After resection of residual masses patients underwent followup examinations at 3 month intervals during the first and second year. In the third year patients were seen every 6 months and thereafter annually. Examinations included physical examination, laboratory testing including serum tumour markers, chest radiography and abdominal and thoracic CT scans.
Rests
Histological examination of specimens from the first surgical intervention after chemotherapy disclosed necrosis/fibrosis in 15 (39%), mature teratoma in 19 (50%) and undifferentiated tumour in four cases (11/%). During the second postchemotherapy operation necrosis/fibrosis was identified in 22 patients (58%), differentiated teratoma in 15 (40%) and undifferentiated tumour in one case (3%). The last patient also had undifferentiated tumour in his specimen resected during the first surgical intervention. During the third intervention one patient had resected undifferentiated tumour, while mature teratoma and necrosis were found at the first and second procedures. In 12 of the 38 patients (32%) necrosis/fibrosis was found in all surgically removed specimens. Differentiated teratoma was identified in ten patients (26%) at all operations.
Fifteen patients (39%) had dissimilar histological findings at post-chemotherapy surgical procedures (Table I) . Undifferentiated tumour tissue is regarded as less favourable than mature teratoma and the latter less favourable than necrosis/fibrosis. Considering these criteria, in 12 cases less favourable histological findings were identified at the first surgical intervention and in three cases at the second operation. In 12 patients who underwent both RPLND and lung resection a less favourable histology was found in the retroperitoneum in nine cases and in the lung in three cases. Of nine patients who harboured necrosis/fibrosis at RPLND, in eight cases necrosis/fibrosis was also identified at thoracotomy, and only one patient showed mature teratoma at thoracic surgery. Conversely, of 17 patients who harboured necrosis/fibrosis at thoracotomy, only eight also showed necrosis/fibrosis at RPLND, while in eight cases mature teratoma was identified, and in one patient undifferentiated tumour.
Considering all 38 patients, complete necrosis was much more frequently found at lung resection (61%) than at RPLND (34%) (P = 0.03, chi-square test) (Table II) . Conversely, mature teratoma was more frequently identified at RPLND (59%) than at thoracotomy (28%) (P = 0.01, chisquare test). Of the eight patients who underwent bilateral thoracotomies for lung resection, necrosis/fibrosis, differentiated teratoma and undifferentiated tumour were identified at both surgical interventions in four, one and one cases respectively. Two patients showed less favourable histological findings at the first operation.
Of the 16 (Tiffany et al., 1986) . Although no conclusion has been reached about whether all patients should undergo excision of post-chemotherapy residual masses (Levitt et al., 1985; Donohue et al., 1987; Fossa et al., 1992) , the majority of reports recommend the excision of all tumour residuals. Postchemotherapy surgery allows an accurate staging which helps to define the need for further treatment (Fox et al., 1993) and which also has prognostic implications. The majority of investigators found that patients with complete necrosis/ fibrosis did better than those with mature teratoma and the latter better than those with undfferentiated tumour in their post-chemotherapy surgical specimens (Tait et al., 1984; Gedler et al., 1989; Staehker et al., 1989 , Jansen et al., 1991 Mead et al., 1992; Hendry et al., 1993) . However, two reports could not confirm the prognostic relevance of histological features at post-chemotherapy surgery (Harding et al., 1989; Steyerberg et al., 1993) . Another criterion which appears to be associated with a favourable clinical outcome is the completeness of surgical resection (Harding et al., 1989; Jansen et al., 1991; Hendry et al., 1993; Steyerberg et al., 1993 (Freiha et al., 1984) , whereas a higher rate of undifferentiated tumour was found in patients treated with only three cycles of chemotherapy (Pizzocaro et al., 1985) . Surgical resection of residual masses containing undifferentiated tumour may be curative in some patients and defines the need for firther treatment with chemotherapy (Fox et al., 1993) . Patients with differentiated teratoma in tumour residuals may also benefit from post-chemotherapy surgery, as mature teratoma may have the potential to grow (Logothetis et al., 1982) , and in some cases it may be responsible for late tumour recurrences (Roth et al., 1988; Gelderman et al., 1989) . If, however, necrosis/fibrosis is found in all resected specimens, probably no benefit is gained from surgical interventions. Although morbidity of post-chemotherapy surgery is tolerable, and mortality is low in specialised centres, the question rises of whether the number of surgical interventions could be reduced safely in selected patients. Since radical RPLND leads to dry ejaculation in a considerable proportion of patients, a case in point would be the elimination of RPLND in patients with negative histological findings at thoracotomy. We compared the response to chemotherapy at various anatomical sites and detected dissimilar histological findings in 39% of patients. Other investigators described different pathological features in 29%, 35% and 47% (Mandelbaum et al., 1983; Tiffany et al., 1986; Qvist et al., 1991) . Of our patients who underwent resection of both lungs and RPLND, 9 of 12 harboured the less favourable histological features in the retroperitoneum. Similar observations were made by two of the aforementioned investigators (Mandelbaum et al., 1983; Tiffany et al., 1986) ; while the third report, which included only 15 patients, could not confirm this finding (Qvist et al., 1991 ). Our data demonstrate that patients harbouring necrosis/fibrosis at RPLND have a high chance of finding necrosis/fibrosis also at thoracotomy. Conversely, patients showing necrosis/fibrosis at thoracotomy often do not demonstrate the same favourable histology at RPLND.
It is of interest that patients who underwent resection of both abdominal and thoracic residual masses demonstrated more frequently mature teratoma than patients who required post-chemotherapy surgery only at one anatomical site (Donohue & Rowland, 1984) . In agreement with other reports (Donohue et al., 1987; Gelderman et al., 1988; Toner et al., 1990; Qvist et al., 1991) , we found that the lack of mature teratoma in the primary tumour was associated with a lower probability of finding differentiated teratoma at postchemotherapy surgery. However, 44% of these patients showed mature teratoma, most often at the retroperitoneal space. In a large series, 33% of patients whose primary tumours did not contain mature teratomatous elements demonstrated differentiated teratoma at post-chemotherapy RPLND (Toner et al., 1990) . Conversely, it is notable that all patients of our series with a histological diagnosis of malignant teratoma intermediate showed mature teratoma at postchemotherapy surgery, at least at one anatomical site. An association between malignant teratoma intermediate in the primary tumour and a high frequency of differentiated teratoma resected at post-chemotherapy surgery has been described by several investigators (Donohue et al., 1987; Gelderman et al., 1988; Toner et al., 1990) .
It is of note that in six patients relapses occurred in the lungs after thoracotomy, in five of whom surgery had been regarded as complete. However, in one patient only necrosis was identified at repeat thoracotomy, and a further patient relapsed only with mature teratoma underscoring the need for histological confirmation in marker-negative recurrent disease. Furthermore, it is of interest that four relapses occurred in the brain either alone or in association with a relapse at other sites. The central nervous system has been recognised as a sanctuary site of relapse in chemotherapytreated germ cell tumours (Gerl et al., 1994) .
In conclusion, histological findings in residual masses following chemotherapy for advanced NSGCTs cannot be extrapolated from one anatomical site to another. Since no reliable criteria exist to predict the precise nature of postchemotherapy residual masses, surgical excision of all tumour residuals is usually advised. As the retroperitoneal space often harbours less favourable histological findings, elimination of RPLND in patients with necrosis/fibrosis at thoracotomy is discouraged. Conversely, close observation of small continuously shrinking pulmonary residuals may be justified in patients with necrosis/fibrosis at RPLND.
